The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells

Leukemia Research Reports

Volumn 3, Issue 2, 2014, Pages 79-82

  Baev, Denis V ^a   Krawczyk, Janusz ^b   O'Dwyer, Michael ^a,b   Szegezdi, Eva ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

ABT 737; Acute myeloid leukemia; BH3 mimetic; CD34+ CD38 ; Putative leukemic stem cells

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASE REPORT; CD34 SELECTION; CD38- T LYMPHOCYTE; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; PALLIATIVE THERAPY; T LYMPHOCYTE;

EID: 84907553868     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2014.06.001     Document Type: Article

References (10)

1. Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 2011, 11:56-71.
2. Doan P., Chute J. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 2012, 26(1):54-62.
3. Park J.R., Bernstein I.D., Hockenbery D.M. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood 1995, 86(3):868-876.
4. Andreeff M., Jiang S., Zhang X., Konopleva M., Estrov Z., Snell V.E., et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999, 13(11):1881-1892.
5. Szegezdi E., Reis C.R., van der Sloot A.M., Natoni A., O'Reilly A., Reeve J., et al. Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 2011, 15(10):2216-2231.
6. Dariushnejad H., Zarghami N., Rahmati M., Ghasemali S., Sadeghi Z., Davoodi Z., et al. ABT-737, synergistically enhances daunorubicin-mediated apoptosis in acute myeloid leukemia cell lines. Adv Pharm Bull 2014, 4(2):185-189.
7. Bogenberger J.M., Kornblau S.M., Pierceall W.E., Lena R., Chow D., Shi C.X., et al. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014, 28(8):1657-1665.
8. Ruth C., Morrell et al. The BH3 mimetic, ABT-737, overcomes stromal-mediated pro-survival signals and synergizes with PHA-767491, a dual Cdc7/CDK9 inhibitor, in acute myeloid leukemia. 53rd ASH annual meeting abstract; 2010.
9. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10(5):375-388.
10. Goichi Yoshimoto, Miyamoto T., Jabbarzadeh-Tabrizi S., Iino T., Rocnik J.L., Kikushige Y., et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009, 114(24):5034-5043.